<DOC>
	<DOC>NCT00695110</DOC>
	<brief_summary>The purpose of this pharmacokinetic study is to determine whether oral testosterone ester formulations can be used effectively to treat men with low testosterone.</brief_summary>
	<brief_title>Pharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Male, ages 1868 Serum total testosterone less than or equal to 275 ng/dL Significant intercurrent disease of any type, in particular, liver, kidney or heart disease, uncontrolled diabetes mellitus or psychiatric illness. Abnormal prostate digital rectal examination, elevated PSA, AUA symptom score of &gt;15, and/or history of prostate cancer. Hematocrit of &lt;35 or &gt;50% BMI &gt;36 Serum transaminases &gt; 2 times upper limit of normal or serum bilirubin &gt; 2.0 mg/dL</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>testosterone</keyword>
	<keyword>male hypogonadism</keyword>
	<keyword>low testosterone</keyword>
</DOC>